|
Activated B-cell type diffuse large B-cell lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In conclusion, these results provide novel clinical and biological insight into the tumor-suppressive role of PRDM1/BLIMP-1 in ABC-DLBCL patients and suggest that loss of PRDM1/BLIMP-1 function contributes to the overall poor prognosis of ABC-DLBCL patients.
|
27568520 |
2017 |
|
Activated B-cell type diffuse large B-cell lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma.
|
21156281 |
2010 |
|
Activated B-cell type diffuse large B-cell lymphoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We report here that the BLIMP1 gene is inactivated by structural alterations in 24% (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-like (n = 0/37) or unclassified (n = 0/21) DLBCL.
|
16492805 |
2006 |
|
Activated B-cell type diffuse large B-cell lymphoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Here, we show that N-terminal misfolding mutations in ABC-DLBCL render Blimp-1 protein susceptible to proteasome-mediated degradation but spare its transcription-regulating activity.
|
28842558 |
2017 |
|
Acute periodontitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Variants at IRF5 and PRDM1 showed association with AgP.
|
25263394 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Interrogation of microarray datasets demonstrated elevated BLIMP1 RNA expression in lung adenocarcinoma, pancreatic ductal carcinomas, head and neck tumors as well as in glioblastomas.
|
22438909 |
2012 |
|
Adult Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our results expand the spectrum of lymphoid malignancies in which PRDM1 may have a tumor suppressor role and identify an epigenetic event that likely contributes to the pathogenesis of BL.
|
25382611 |
2014 |
|
Adult Classical Hodgkin Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
PRDM1 protein was expressed in some cases of B-cell neoplasia, i.e. chronic lymphocytic leukemia/small lymphocytic lymphoma (15%), diffuse large B-cell lymphoma (43%), classical Hodgkin's lymphoma (41%) and also in T-cell lymphoma (23%).
|
16585013 |
2006 |
|
Adult Classical Hodgkin Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we showed that lowly expressed CD99 protein in cHL cell lines and primary cHL cases correlates with the deficient expression of the positive regulatory domain 1 (PRDM1/BLIMP1).
|
22020966 |
2012 |
|
Adult Classical Hodgkin Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Whereas these factors typically induce the master regulator of plasma cell (PC) differentiation PRDM1/BLIMP-1, levels of PRDM1 remain low in cHL.
|
25232062 |
2014 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Recently, new roles for Blimp-1 have been revealed, as a suppressor of diffuse large B cell lymphoma and as a key regulator of T-cell differentiation.
|
17291741 |
2007 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma.
|
16492805 |
2006 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma.
|
17379744 |
2007 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Here, we describe novel mutations in the BLIMP1 gene in 2 of 15 (13%) cases of B-cell lymphoma (two cases of primary effusion lymphoma and 13 cases of diffuse large B-cell lymphoma).
|
17213024 |
2007 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Taken together with previous reports, the present results suggest that two key transcription factors for the plasmacytic differentiation, XBP1 and BLIMP1, are involved in the pathogenesis in diffuse large B-cell lymphoma.
|
19380033 |
2009 |
|
Adult Diffuse Large B-Cell Lymphoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
Unexpectedly, a subset of diffuse large B-cell lymphoma expressed PRDM1, lacked detectable plasmablastic or immunoblastic changes and displayed more aggressive behavior, with a shorter failure-free survival.
|
16585013 |
2006 |
|
Adult Diffuse Large Cell Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We report here that the BLIMP1 gene is inactivated by structural alterations in 24% (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-like (n = 0/37) or unclassified (n = 0/21) DLBCL.
|
16492805 |
2006 |
|
Adult Fibrosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
B-lymphocyte-induced maturation protein-1 (Blimp1), a transcriptional repressor of negative regulators of osteoclastogenesis, was also downregulated by Ambn, resulting in the elevated expression of v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (MafB), B-cell lymphoma 6 (Bcl6), and interferon regulatory factor-8 (Irf8).
|
30105896 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma.
|
21785431 |
2011 |
|
Adult Hodgkin Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
MiRNA-mediated down-regulation of PRDM1/Blimp-1 may contribute to the phenotype maintenance and pathogenesis of HRS cells by interfering with normal B-cell terminal differentiation, thus representing a novel molecular lesion, as well as a potential therapeutic target in HL.
|
18583325 |
2008 |
|
Adult Hodgkin Lymphoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
It has been shown in DLBCL and Hodgkin lymphoma that PRDM1 is downregulated by cellular microRNAs.
|
26530011 |
2016 |
|
Adult Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Mechanistically, whereas wild-type Blimp-1 metabolism is triggered in the nucleus through PML-mediated sumoylation, the degradation of lymphoma-associated mutants is accelerated by subversion of this pathway to Hrd1-mediated cytoplasmic sequestration and ubiquitination.
|
28842558 |
2017 |
|
Adult Lymphoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
BLIMP1 is frequently inactivated in a variety of lymphomas, including diffuse large B cell lymphomas, Natural Killer cell lymphoma and anaplastic large T cell lymphoma.
|
25115512 |
2015 |
|
Adult Lymphoma
|
0.040 |
PosttranslationalModification
|
disease |
BEFREE |
In vivo genomic footprinting of the PRDM1 promoter in unstimulated lymphoma and myeloma cells reveals multiple common in vivo occupied elements throughout the promoter.
|
19828640 |
2009 |
|
Adult Lymphoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
PRDM1 protein expression was recently demonstrated in a subset of diffuse large B-cell lymphoma (DLBCL) with aggressive behavior, a type of lymphoma for which rituximab associated with chemotherapy (R-CHOP) is now widely indicated.
|
17379744 |
2007 |